# Risk of ophthalmic adverse events in patients treated with immune checkpoint inhibitor regimens: A systematic review and meta-analysis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/risk-of-ophthalmic-adverse-events-in-patients-treated-with-immune-checkpoint-2/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yanli Hou,Di-ya Wang,Ruyue Tian,Jiexuan Hu,Wei Wang,Qiang Su,Yanling Wang,Miguel N. Burnier |
| Citations | 0 |
| DOI | 10.21203/rs.2.15875/v1 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://doi.org/10.21203/rs.2.15875/v1 |
| OpenAlex ID | https://openalex.org/W4235783426 |
| Type | preprint |
| Year | 2019 |

## Paper authors

- [Di-ya Wang](https://scholariq.org/researchers/di-ya-wang/)

## Paper journal

- [Research Square](https://scholariq.org/journals/research-square/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Ocular Oncology and Treatments](https://scholariq.org/topics/ocular-oncology-and-treatments/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.